StreetInsider.com News Articles

Accendra Health Announces Third Quarter 2026 Earnings Release Date and Conference Call

Thu, 22 Oct 2026 16:05:00 -0400

RICHMOND, Va.--(BUSINESS WIRE)--

Accendra Health, Inc. (NYSE: ACH) (the “Company”) plans to release financial results for the third quarter of 2026 on Thursday, November 5, 2026, after trading ends on the New York Stock Exchange.

The Company will host a conference call for investors and analysts at 5:00 p.m. EST on the same day. Participants may access the call via the toll-free dial-in number at 1-833-461-5787, or the toll dial-in number at 1-585-542-9983. The conference ID access code is 829 856 607.

All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the Investor Relations

Accendra Health Announces Third Quarter 2026 Earnings Release Date and Conference Call

Thu, 22 Oct 2026 16:05:00 -0400

RICHMOND, Va.--(BUSINESS WIRE)--

All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the Investor Relations

Form PRE 14A ACCENDRA HEALTH INC/VA/ For: Oct 19

Mon, 19 Oct 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20261019/27204778.html

Accendra Health Inc. (ACH) PT Lowered to $0.50 at Baird

Mon, 12 Oct 2026 07:22:22 -0400

Baird analyst Eric Coldwell lowered the price target on Accendra Health Inc. (NYSE: ACH) to $0.50 (from $1.50) while maintaining a Neutral rating.

Form 8-K ACCENDRA HEALTH INC/VA/ For: Oct 06

Fri, 09 Oct 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20261009/27171630.html

Accendra Health gets NYSE notice over low share price

Fri, 09 Oct 2026 16:05:14 -0400

Accendra Health, Inc. (NYSE: ACH) received a notice from the New York Stock Exchange on October 6, 2026, stating that the company is not in compliance with the exchange's continued listing standards. The notice was triggered because the average closing price of the company's Class A Common Stock fell below $1.00 per share over a consecutive 30 trading-day period.

The notice does not result in the immediate delisting of the stock. Accendra Health said it intends to respond to the NYSE within ten business days, affirming its intent to cure the deficiency. Under NYSE rules, the company has six months from

Accendra Health Receives Continued Listing Standard Notice from NYSE; Intends to Cure Deficiency and Return to Compliance with NYSE Listing Standard

Fri, 09 Oct 2026 16:05:00 -0400

RICHMOND, Va.--(BUSINESS WIRE)-- Accendra Health, Inc. (NYSE: ACH) (the Company) today announced that on October 6, 2026, it received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) notifying the Company that it is not in compliance with the NYSE’s continued listing standards because the average closing price of the Company’s Class A Common Stock (the “Common Stock”) was less than $1.00 per share over a consecutive 30 trading-day period. The Notice does not result in the immediate delisting of the Company’s Common Stock from the NYSE.

The Company intends to respond to the

Accendra Health Receives Continued Listing Standard Notice from NYSE; Intends to Cure Deficiency and Return to Compliance with NYSE Listing Standard

Fri, 09 Oct 2026 16:05:00 -0400

The Company intends to respond to the

Form SCHEDULE 13G ACCENDRA HEALTH INC/VA/ Filed by: BANK OF AMERICA CORP /DE/

Wed, 07 Oct 2026 11:29:00 -0400

si-local-file:///var/storage/secattach/20261007/27159887.html

Form 4 ACCENDRA HEALTH INC/VA/ For: Oct 05 Filed by: Gardner-Smith Kenneth

Tue, 06 Oct 2026 20:16:00 -0400

si-local-file:///var/storage/secattach/20261006/27156650.html

Form 8-K/A ACCENDRA HEALTH INC/VA/ For: Sep 16

Mon, 28 Sep 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260928/27115411.html

Form 4 ACCENDRA HEALTH INC/VA/ For: Sep 23 Filed by: Leon Jonathan A

Thu, 24 Sep 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260924/27102600.html

Form 8-K ACCENDRA HEALTH INC/VA/ For: Sep 16

Thu, 17 Sep 2026 06:36:00 -0400

si-local-file:///var/storage/secattach/20260917/27072434.html

Accendra Health names new CEO and chief commercial officer

Thu, 17 Sep 2026 06:30:21 -0400

Accendra Health, Inc. (NYSE: ACH) has named Kenneth Gardner-Smith as its next President and Chief Executive Officer, according to a company statement. Gardner-Smith, who has served on the company's Board of Directors since March 2022, is expected to assume the role early in the fourth quarter of 2026, succeeding Edward A. Pesicka, who announced his retirement in August.

Gardner-Smith currently serves as Chief Executive Officer of Veritas Veterinary Partners, a national specialty and emergency veterinary platform, a role he has held since 2024. Before that, he spent 13 years at DaVita in various operating roles, including nine years managing $1.5 billion

Accendra Health names new CEO and chief commercial officer

Thu, 17 Sep 2026 06:30:21 -0400

Accendra Health Names Kenneth Gardner-Smith as President and Chief Executive Officer to Lead the Company’s Next Chapter of Growth

Thu, 17 Sep 2026 06:30:00 -0400

Gardner-Smith to Succeed Ed Pesicka Following Previously Announced Retirement

Company Announces Scott Lloyd as Chief Commercial Officer

RICHMOND, Va.--(BUSINESS WIRE)-- Accendra Health, Inc. (NYSE: ACH) (the “Company”) today named Kenneth Gardner-Smith as the Company’s next President and Chief Executive Officer. Gardner-Smith, who has served on the Company’s Board of Directors since March 2022, is expected to assume the role early in the fourth quarter 2026. He will succeed Edward A. Pesicka, who announced his intent to retire in August.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260917344754/en/

Gardner-Smith to Succeed Ed Pesicka Following Previously Announced Retirement

Company Announces Scott Lloyd as Chief Commercial Officer

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260917344754/en/